Pettus J, et al. - Among 638 patients with type 1 diabetes (T1D), researchers compared the safety and effectiveness of insulin glargine 300 units/mL (Gla-300) vs insulin glargine 100 units/mL (Gla-100). For this multicenter (N = 104), randomized controlled phase 4 study, participants were randomized 1:1 to self-inject Gla-300 or Gla-100 every morning for sixteen weeks. In patients with glycated hemoglobin (HbA1c) <7.5% at week 16, exploratory analyses were performed. At the end of the study in the modified intent-to-treat population of relatively well-controlled patients with T1D, time in range and glycemic variability were comparable for Gla-300 and Gla-100 recipients. Exploratory analyses proposed that, in patients with end-of-study HbA1c <7.5%, Gla-300 offered timely improvements in range relative to Gla-100.